South America Meglitinide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America meglitinide market size was valued at USD 0.21 billion in 2025 and is estimated to grow from USD 0.22 billion in 2026 to reach USD 0.27 billion by 2031, at a CAGR of 4.56% during the forecast period (2026-2031). This report is segmented by Drug Type (Repaglinide, Nateglinide, Other Meglitinide), Dosage Form (Immediate-Release Tablets, Fixed-Strength Tablets, Combination Regimens), Distribution Channel (Retail, Hospital, Online Pharmacies), and Geography (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). The Market Forecasts are Provided in Terms of Value (USD).

South America Meglitinide Market Trends and Insights

Expanding Type 2 Diabetes Treatment Pool

South America’s diabetes burden provides a substantial demand base for the South America meglitinide market. The region had 35.4 million adults with diabetes in 2024, and the total is projected to reach 52 million by 2050. Brazil accounted for 17.0 million cases, while Argentina had 4.3 million cases and an age-standardized prevalence of 14%. As 30.4% of regional cases were undiagnosed in 2024, expanded screening can increase the treatment pool. Diabetes-related health expenditure reached USD 81 billion in 2024, underscoring the scale of healthcare demand.

Meal-Time Flexibility and Short-Acting Alternatives

Meglitinides support patients with irregular eating patterns by stimulating insulin release in response to meals. This flexibility benefits shift workers, informal workers, and older adults with variable meal schedules. Nateglinide has a faster onset of action and a lower hypoglycemia risk than repaglinide, supporting its use in selected private specialist settings. Colombia’s 2025 clinical guideline recognized meal-related glucose excursions as a treatment consideration, sustaining a limited role for meglitinides when first-line therapy is unsuitable or insufficient.

Non-Incorporation in Brazil’s Sistema Único de Saúde Treatment Protocol

Brazil’s public health system shapes access in the South America meglitinide market, as SUS covers 76% of the population. The February 2026 PCDT DM2 update listed metformin, gliclazide, glibenclamide, dapagliflozin, and insulin analogs but excluded meglitinides. Repaglinide also remained outside RENAME 2024 and lacked support under Santa Catarina’s state dispensing protocol, limiting demand primarily to private retail pharmacies and supplementary insurance channels. The absence of routine public reimbursement increases patient cost exposure and demand volatility, while the 2026 Brazilian Diabetes Society guidance prioritized gliclazide MR among secretagogues.

Other drivers and restraints analyzed in the detailed report include:

• Generic Price Accessibility
• Local Registration and Supply-Chain Localization
• Therapeutic Substitution by Newer Antidiabetic Classes

Segment Analysis

Repaglinide held 65.12% of the South America meglitinide market in 2025, supported by its long-standing registration history and broad generic base in Brazil. EMS S.A. and Glenmark Farmacêutica market repaglinide products in Brazil through distinct brands and retail channels. The 1 mg and 2 mg formulations have broad availability across pharmacy chains, supporting treatment continuity for patients and prescribers familiar with the molecule. Its established market presence and lower cost in private pharmacies reinforce its position despite guidelines favoring other drug classes for patients with specific comorbidities.

Nateglinide is forecast to be the fastest-growing drug type, expanding at a CAGR of 6.89% from 2026 to 2031. Its faster insulin secretion profile and lower hypoglycemia risk relative to repaglinide support use among some older patients and those with cardiovascular comorbidities. Endocrinologists in private practice may prefer nateglinide for patients taking multiple medications who require a lower interaction burden. Novartis AG’s Starlix brand, licensed from KISSEI Pharmaceutical, maintains visibility in specialist centers and hospital pharmacies, creating a two-track market alongside repaglinide’s broad generic retail presence.

Complete Report Scope:

• By Drug Type
  • Repaglinide
  • Nateglinide
  • Other Meglitinide
• By Dosage Form
  • Immediate-Release Tablets
  • Fixed-Strength Tablets
  • Combination and Co-Prescribed Regimens
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

• Aché Laboratórios Farmacêuticos S.A.
• Biocon
• Boehringer Ingelheim
• Eli Lilly and Company
• EMS S.A.
• Eurofarma Laboratórios S.A.
• Fundação para o Remédio Popular - FURP
• Glenmark Pharmaceuticals
• Hypera S.A.
• KISSEI PHARMACEUTICAL CO., LTD.
• Lupin
• Merck
• Novartis
• Novo Nordisk
• Pfizer
• Sandoz Group AG
• Sanofi
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Limited
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support